BCV
SGMO

Banque Cantonale Vaudoise’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Banque Cantonale Vaudoise’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-93
Closed – – 1283
2022
Q2 		$0 Hold
93
– – ﹤0.01% 1346
2022
Q1 		$1K Hold
93
– – ﹤0.01% 1290
2021
Q4 		$1K Sell
93
-36,444
-100% -$317K ﹤0.01% 1316
2021
Q3 		$329K Sell
36,537
-2,713
-7% -$26.8K 0.01% 690
2021
Q2 		$470K Sell
39,250
-1,444
-4% -$16.3K 0.02% 613
2021
Q1 		$510K Sell
40,694
-8,345
-17% -$112K 0.03% 537
2020
Q4 		$765K Buy
49,039
+26,088
+114% +$306K 0.04% 374
2020
Q3 		$217K Buy
22,951
+283
+1% +$3.06K 0.01% 659
2020
Q2 		$203K Buy
22,668
+2,178
+11% +$20.2K 0.01% 645
2020
Q1 		$131K Sell
20,490
-1,984
-9% -$14.7K 0.01% 717
2019
Q4 		$188K Buy
+22,474
New +$207K 0.01% 735

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Banque Cantonale Vaudoise's SGMO Position: Q3 2022 in Review

Banque Cantonale Vaudoise sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2022, closing a stake of 93 shares.

Banque Cantonale Vaudoise first reported a position in SGMO in Q4 2019 and held it in 11 quarters. The position peaked at $765K in Q4 2020. 197 funds tracked by Wall St. Rank hold SGMO as of Q3 2022.

  • Banque Cantonale Vaudoise reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2022 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 93 SANGAMO THERAPEUTICS INC shares in Q3 2022.
  • Banque Cantonale Vaudoise first reported a position in SANGAMO THERAPEUTICS INC in Q4 2019 and held it in 11 quarters.
  • Banque Cantonale Vaudoise's SANGAMO THERAPEUTICS INC position peaked at $765K in Q4 2020.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2022, filed 17 Oct 2022.